The estimated Net Worth of Kevin R Kelly is at least $65.8 Tausend dollars as of 23 March 2018. Kevin Kelly owns over 230 units of Hookipa Pharma Inc stock worth over $1,859 and over the last 16 years Kevin sold HOOK stock worth over $63,971.
Kevin has made over 5 trades of the Hookipa Pharma Inc stock since 2009, according to the Form 4 filled with the SEC. Most recently Kevin bought 230 units of HOOK stock worth $4,278 on 23 March 2018.
The largest trade Kevin's ever made was buying 23,100 units of Hookipa Pharma Inc stock on 6 April 2009 worth over $27,720. On average, Kevin trades about 1,455 units every 156 days since 2009. As of 23 March 2018 Kevin still owns at least 352 units of Hookipa Pharma Inc stock.
You can see the complete history of Kevin Kelly stock trades at the bottom of the page.
Kevin's mailing address filed with the SEC is 929 NORTH RUSSELL STREET, , PORTLAND, OR, 97227.
Over the last 21 years, insiders at Hookipa Pharma Inc have traded over $12,222,300 worth of Hookipa Pharma Inc stock and bought 1,455,824 units worth $18,573,557 . The most active insiders traders include Group, Llc Green Jeremy Red..., Bros. Advisors Lp Baker Bro... und Deventer Sander Van. On average, Hookipa Pharma Inc executives and independent directors trade stock every 94 days with the average trade being worth of $180,581. The most recent stock trade was executed by Reinhard Kandera on 21 August 2023, trading 7,000 units of HOOK stock currently worth $5,110.
hookipa pharma inc. is a clinical stage company developing products to prevent and cure infectious diseases and cancer. with this goal in mind we created unique and cutting-edge technologies which reprogram and stimulate the immune system. our arenavirus technologies, vaxwave®, a replication-deficient viral vector, and therat®, an attenuated replicating vector, induce potent pathogen-neutralizing antibodies and cd8+ t cells. both, vaxwave® and therat®, can be administered repeatedly while maintaining their efficacy. therat® induced cd8+ t cell responses to tumor antigens reach frequencies and potencies matching or exceeding those observed after adoptive t cell therapy. hookipa’s “off-the shelf” viral vectors are administered systemically. they target dendritic cells in vivo and activate the immune system. in immune-oncology, this mechanism enables to fight solid tumors systemically, both primary and secondary (metastatic). at hookipa we have successfully completed a phase 1 trial of a
Hookipa Pharma Inc executives and other stock owners filed with the SEC include: